{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T17:06:54Z","timestamp":1788973614836,"version":"build-2803163510"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"DOI":"10.1007\/s40120-026-01024-9","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T16:07:15Z","timestamp":1788970035000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of Rimegepant for the Acute Treatment of Migraine Among Participants Using Different Types of Preventive Therapy: Analyses from CONFIDENCE"],"prefix":"10.1007","clinical-trial-number":[{"clinical-trial-number":"nct06467370","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2652-2897","authenticated-orcid":false,"given":"Richard B.","family":"Lipton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3260-5904","authenticated-orcid":false,"given":"Peter J.","family":"Goadsby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0796-4702","authenticated-orcid":false,"given":"Patricia","family":"Pozo-Rosich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2519-5884","authenticated-orcid":false,"given":"Alexandre","family":"Urani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2780-4776","authenticated-orcid":false,"given":"Giorgio","family":"Lambru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7780-7086","authenticated-orcid":false,"given":"Todd J.","family":"Schwedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8072-1489","authenticated-orcid":false,"given":"Kristina M.","family":"Fanning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2034-2934","authenticated-orcid":false,"given":"Ryan C.","family":"Bostic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9963-6863","authenticated-orcid":false,"given":"Feng","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1648-8621","authenticated-orcid":false,"given":"Lucy","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6925-7099","authenticated-orcid":false,"given":"Karin","family":"Hygge Blakeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"1024_CR1","doi-asserted-by":"publisher","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38:1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202.","DOI":"10.1177\/0333102417738202"},{"key":"1024_CR2","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s40122-024-00690-7","volume":"14","author":"L Dong","year":"2025","unstructured":"Dong L, Dong W, Jin Y, Jiang Y, Li Z, Yu D. The global burden of migraine: a 30-year trend review and future projections by age, sex, country, and region. Pain Ther. 2025;14:297\u2013315. https:\/\/doi.org\/10.1007\/s40122-024-00690-7.","journal-title":"Pain Ther"},{"key":"1024_CR3","doi-asserted-by":"publisher","DOI":"10.1177\/03331024241252666","volume":"44","author":"F Puledda","year":"2024","unstructured":"Puledda F, Sacco S, Diener H-C, et al. International Headache Society global practice recommendations for the acute pharmacological treatment of migraine. Cephalalgia. 2024;44:03331024241252666. https:\/\/doi.org\/10.1177\/03331024241252666.","journal-title":"Cephalalgia"},{"key":"1024_CR4","doi-asserted-by":"publisher","DOI":"10.1177\/03331024241269735","volume":"44","author":"F Puledda","year":"2024","unstructured":"Puledda F, Sacco S, Diener HC, et al. International Headache Society global practice recommendations for preventive pharmacological treatment of migraine. Cephalalgia. 2024;44:3331024241269735. https:\/\/doi.org\/10.1177\/03331024241269735.","journal-title":"Cephalalgia"},{"key":"1024_CR5","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","volume":"61","author":"J Ailani","year":"2021","unstructured":"Ailani J, Burch RC, Robbins MS, Board of Directors of the American Headache Society. The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61:1021\u201339. https:\/\/doi.org\/10.1111\/head.14153.","journal-title":"Headache"},{"key":"1024_CR6","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/head.14692","volume":"64","author":"AC Charles","year":"2024","unstructured":"Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A, American Headache Society. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American Headache Society position statement update. Headache. 2024;64:333\u201341. https:\/\/doi.org\/10.1111\/head.14692.","journal-title":"Headache"},{"key":"1024_CR7","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1111\/head.15016","volume":"65","author":"A Ezzati","year":"2025","unstructured":"Ezzati A, Fanning KM, Teichrow D, Urani A, Cadiou F, Lipton RB. Headache assessment via digital platform in United States: baseline study characteristics, diagnosis, and treatment patterns. Headache. 2025;65:1428\u201338. https:\/\/doi.org\/10.1111\/head.15016.","journal-title":"Headache"},{"key":"1024_CR8","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s40120-024-00669-8","volume":"13","author":"RB Lipton","year":"2024","unstructured":"Lipton RB, Ailani J, Blumenfeld AM. What is combination treatment in migraine? Moving toward a uniform definition of a familiar principle. Neurol Ther. 2024;13:1535\u201340. https:\/\/doi.org\/10.1007\/s40120-024-00669-8.","journal-title":"Neurol Ther"},{"key":"1024_CR9","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/head.70043","volume":"66","author":"S Hutchinson","year":"2026","unstructured":"Hutchinson S, Johnston E, Nicholson RA, et al. Unmet treatment needs in migraine: results of the OVERCOME (US) study. Headache. 2026;66:896\u2013908. https:\/\/doi.org\/10.1111\/head.70043.","journal-title":"Headache"},{"key":"1024_CR10","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1080\/17581869.2025.2494494","volume":"15","author":"L Pellesi","year":"2025","unstructured":"Pellesi L, Jedie B, Barhum F, Al-Abdullah S, Martelletti P, Xiao Z. Head-to-head relief: ubrogepant, rimegepant, and zavegepant in migraine treatment. Pain Manag. 2025;15:279\u201384. https:\/\/doi.org\/10.1080\/17581869.2025.2494494.","journal-title":"Pain Manag"},{"key":"1024_CR11","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1212\/con.0000000000000199","volume":"21","author":"SD Silberstein","year":"2015","unstructured":"Silberstein SD. Preventive migraine treatment. Continuum (Minneap Minn). 2015;21:973\u201389. https:\/\/doi.org\/10.1212\/con.0000000000000199.","journal-title":"Continuum (Minneap Minn)"},{"key":"1024_CR12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s10194-023-01594-1","volume":"24","author":"C Lampl","year":"2023","unstructured":"Lampl C, MaassenVanDenBrink A, Deligianni CI, et al. The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis. J Headache Pain. 2023;24:56. https:\/\/doi.org\/10.1186\/s10194-023-01594-1.","journal-title":"J Headache Pain"},{"key":"1024_CR13","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231159366","volume":"43","author":"F Haghdoost","year":"2023","unstructured":"Haghdoost F, Puledda F, Garcia-Azorin D, Huessler E-M, Messina R, Pozo-Rosich P. Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: a systematic review and network meta-analysis of phase 3 randomised controlled trials. Cephalalgia. 2023;43:03331024231159366. https:\/\/doi.org\/10.1177\/03331024231159366.","journal-title":"Cephalalgia"},{"key":"1024_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00328-4","volume":"8","author":"MD Ferrari","year":"2022","unstructured":"Ferrari MD, Goadsby PJ, Burstein R, et al. Migraine. Nat Rev Dis Primers. 2022;8:2. https:\/\/doi.org\/10.1038\/s41572-021-00328-4.","journal-title":"Nat Rev Dis Primers"},{"key":"1024_CR15","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1111\/head.13510","volume":"59","author":"R Hargreaves","year":"2019","unstructured":"Hargreaves R, Olesen J. Calcitonin gene-related peptide modulators \u2013 the history and renaissance of a new migraine drug class. Headache. 2019;59:951\u201370. https:\/\/doi.org\/10.1111\/head.13510.","journal-title":"Headache"},{"key":"1024_CR16","unstructured":"US Food and Drug Administration. Nurtec ODT (rimegepant) prescribing information. 2020. https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=19036. Accessed 22 June 2026."},{"key":"1024_CR17","unstructured":"European Medicines Agency. Vydura (rimegepant) summary of product information. 2022. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vydura. Accessed 22 June 2026."},{"key":"1024_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-026-02421-z","author":"RB Lipton","year":"2026","unstructured":"Lipton RB, Abraham L, Urani A, et al. Consistency of response to rimegepant for the acute treatment of migraine among real-world users \u2013 findings from the prospective observational CONFIDENCE study. J Headache Pain. 2026. https:\/\/doi.org\/10.1186\/s10194-026-02421-z.","journal-title":"J Headache Pain"},{"key":"1024_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01935-8","volume":"26","author":"LF Iannone","year":"2025","unstructured":"Iannone LF, Vaghi G, Sebastianelli G, et al. Effectiveness and tolerability of rimegepant in the acute treatment of migraine: a real-world, prospective, multicentric study (GAINER study). J Headache Pain. 2025;26:4. https:\/\/doi.org\/10.1186\/s10194-024-01935-8.","journal-title":"J Headache Pain"},{"key":"1024_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01873-5","volume":"25","author":"Z Yang","year":"2024","unstructured":"Yang Z, Wang X, Niu M, et al. First real-world study on the effectiveness and tolerability of rimegepant for acute migraine therapy in Chinese patients. J Headache Pain. 2024;25:160. https:\/\/doi.org\/10.1186\/s10194-024-01873-5.","journal-title":"J Headache Pain"},{"key":"1024_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-025-02197-8","volume":"26","author":"J Wang","year":"2025","unstructured":"Wang J, Jiang J, Peng S, et al. Patient-reported outcomes of rimegepant for acute and preventive treatment of migraine in China: a prospective, multicenter, real-world study. J Headache Pain. 2025;26:242. https:\/\/doi.org\/10.1186\/s10194-025-02197-8.","journal-title":"J Headache Pain"},{"key":"1024_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci14121169","author":"EV Dermitzakis","year":"2024","unstructured":"Dermitzakis EV, Rikos D, Vikelis M, et al. Real-world open-label experience with rimegepant for the acute treatment of migraine attacks: a multicenter pilot study. Brain Sci. 2024. https:\/\/doi.org\/10.3390\/brainsci14121169.","journal-title":"Brain Sci"},{"key":"1024_CR23","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.clinthera.2006.09.015","volume":"28","author":"C Michael Hill","year":"2006","unstructured":"Michael Hill C, Sindet-Pederson S, Seymour RA, et al. Analgesic efficacy of the cyclooxygenase-inhibiting nitric oxide donor AZD3582 in postoperative dental pain: comparison with naproxen and rofecoxib in two randomized, double-blind, placebo-controlled studies. Clin Ther. 2006;28:1279\u201395. https:\/\/doi.org\/10.1016\/j.clinthera.2006.09.015.","journal-title":"Clin Ther"},{"key":"1024_CR24","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1016\/j.joms.2010.05.075","volume":"68","author":"JR Zuniga","year":"2010","unstructured":"Zuniga JR, Malmstr\u00f6m H, Noveck RJ, et al. Controlled phase III clinical trial of diclofenac potassium liquid-filled soft gelatin capsule for treatment of postoperative dental pain. J Oral Maxillofac Surg. 2010;68:2735\u201342. https:\/\/doi.org\/10.1016\/j.joms.2010.05.075.","journal-title":"J Oral Maxillofac Surg"},{"key":"1024_CR25","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.eururo.2014.02.013","volume":"67","author":"E Basch","year":"2015","unstructured":"Basch E, Autio KA, Smith MR, et al. Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort. Eur Urol. 2015;67:310\u20138. https:\/\/doi.org\/10.1016\/j.eururo.2014.02.013.","journal-title":"Eur Urol"},{"key":"1024_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-023-01622-0","volume":"24","author":"A Manack Adams","year":"2023","unstructured":"Manack Adams A, Hutchinson S, Engstrom E, et al. Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE study. J Headache Pain. 2023;24:102. https:\/\/doi.org\/10.1186\/s10194-023-01622-0.","journal-title":"J Headache Pain"},{"key":"1024_CR27","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1080\/14737175.2024.2401558","volume":"24","author":"WD Wells-Gatnik","year":"2024","unstructured":"Wells-Gatnik WD, Pellesi L, Martelletti P. Rimegepant and atogepant: novel drugs providing innovative opportunities in the management of migraine. Expert Rev Neurother. 2024;24:1107\u201317. https:\/\/doi.org\/10.1080\/14737175.2024.2401558.","journal-title":"Expert Rev Neurother"},{"key":"1024_CR28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/17581869.2025.2585269","volume":"16","author":"RB Lipton","year":"2026","unstructured":"Lipton RB, Bodhani A, Gao X, et al. Patient-centered outcomes in the acute treatment of migraine: a prospective, real-world, longitudinal survey study (UNIVERSE II) comparing migraine patients who switch from a prior triptan to another triptan or ubrogepant. Pain Manag. 2026;16:39\u201348. https:\/\/doi.org\/10.1080\/17581869.2025.2585269.","journal-title":"Pain Manag"},{"key":"1024_CR29","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40120-023-00556-8","volume":"13","author":"RB Lipton","year":"2024","unstructured":"Lipton RB, Contreras-De Lama J, Serrano D, et al. Real-world use of ubrogepant as acute treatment for migraine with an anti-calcitonin gene-related peptide monoclonal antibody: results from COURAGE. Neurol Ther. 2024;13:69\u201383. https:\/\/doi.org\/10.1007\/s40120-023-00556-8.","journal-title":"Neurol Ther"},{"key":"1024_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104943","author":"R Ornello","year":"2024","unstructured":"Ornello R, Andreou AP, De Matteis E, J\u00fcrgens TP, Minen MT, Sacco S. Resistant and refractory migraine: clinical presentation, pathophysiology, and management. EBioMedicine. 2024. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104943.","journal-title":"EBioMedicine"},{"key":"1024_CR31","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.2147\/jpr.S453937","volume":"17","author":"G Berman","year":"2024","unstructured":"Berman G, Thiry A, Croop R. Safety of rimegepant in patients using preventive migraine medications: a subgroup analysis of a long-term, open-label study conducted in the United States. J Pain Res. 2024;17:1805\u201314. https:\/\/doi.org\/10.2147\/jpr.S453937.","journal-title":"J Pain Res"},{"key":"1024_CR32","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1111\/head.13930","volume":"60","author":"G Berman","year":"2020","unstructured":"Berman G, Croop R, Kudrow D, et al. Safety of rimegepant, an oral CGRP receptor antagonist, plus CGRP monoclonal antibodies for migraine. Headache. 2020;60:1734\u201342. https:\/\/doi.org\/10.1111\/head.13930.","journal-title":"Headache"},{"key":"1024_CR33","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s40120-024-00586-w","volume":"13","author":"T Alsaadi","year":"2024","unstructured":"Alsaadi T, Suliman R, Santos V, et al. Safety and tolerability of combining CGRP monoclonal antibodies with gepants in patients with migraine: a retrospective study. Neurol Ther. 2024;13:465\u201373. https:\/\/doi.org\/10.1007\/s40120-024-00586-w.","journal-title":"Neurol Ther"},{"key":"1024_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fpain.2023.1130239","volume":"4","author":"T Shah","year":"2023","unstructured":"Shah T, Bedrin K, Tinsley A. Calcitonin gene relating peptide inhibitors in combination for migraine treatment: a mini-review. Front Pain Res. 2023;4:1130239. https:\/\/doi.org\/10.3389\/fpain.2023.1130239.","journal-title":"Front Pain Res"},{"key":"1024_CR35","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1111\/head.14871","volume":"65","author":"J Ailani","year":"2025","unstructured":"Ailani J, Lipton RB, Blumenfeld AM, et al. Safety and tolerability of ubrogepant for the acute treatment of migraine in participants taking atogepant for the preventive treatment of episodic migraine: results from the TANDEM study. Headache. 2025;65:1005\u201314. https:\/\/doi.org\/10.1111\/head.14871.","journal-title":"Headache"},{"key":"1024_CR36","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1007\/s12325-021-01923-3","volume":"39","author":"AM Blumenfeld","year":"2022","unstructured":"Blumenfeld AM, Knievel K, Manack Adams A, et al. Ubrogepant is safe and efficacious in participants taking concomitant preventive medication for migraine: a pooled analysis of phase 3 trials. Adv Ther. 2022;39:692\u2013705. https:\/\/doi.org\/10.1007\/s12325-021-01923-3.","journal-title":"Adv Ther"},{"key":"1024_CR37","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000210691","volume":"104","author":"AM Blumenfeld","year":"2025","unstructured":"Blumenfeld AM, He MY, Smith JH, Schlacher C, Lama JC-D, Davis L. Exploratory efficacy results from the TANDEM trial: safety, tolerability, and efficacy of ubrogepant for the acute treatment of migraine in participants taking atogepant for the preventive treatment of episodic migraine (P8-12.002). Neurology. 2025;104:2953. https:\/\/doi.org\/10.1212\/WNL.0000000000210691.","journal-title":"Neurology"},{"key":"1024_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01925-w","volume":"25","author":"L Pellesi","year":"2024","unstructured":"Pellesi L, Garcia-Azorin D, Rubio-Beltr\u00e1n E, et al. Combining treatments for migraine prophylaxis: the state-of-the-art. J Headache Pain. 2024;25:214. https:\/\/doi.org\/10.1186\/s10194-024-01925-w.","journal-title":"J Headache Pain"},{"key":"1024_CR39","doi-asserted-by":"publisher","DOI":"10.1177\/03331024241232944","volume":"44","author":"R Croop","year":"2024","unstructured":"Croop R, Berman G, Kudrow D, et al. A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine. Cephalalgia. 2024;44:03331024241232944. https:\/\/doi.org\/10.1177\/03331024241232944.","journal-title":"Cephalalgia"},{"key":"1024_CR40","doi-asserted-by":"publisher","first-page":"9919773","DOI":"10.1155\/2021\/9919773","volume":"2021","author":"X Xu","year":"2021","unstructured":"Xu X, Ji Q, Shen M. Patient preferences and values in decision making for migraines: a systematic literature review. Pain Res Manag. 2021;2021:9919773. https:\/\/doi.org\/10.1155\/2021\/9919773.","journal-title":"Pain Res Manag"},{"issue":"Suppl 1","key":"1024_CR41","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1046\/j.1526-4610.2002.0420s1003.x","volume":"42","author":"RB Lipton","year":"2002","unstructured":"Lipton RB, Hamelsky SW, Dayno JM. What do patients with migraine want from acute migraine treatment? Headache. 2002;42(Suppl 1):3\u20139. https:\/\/doi.org\/10.1046\/j.1526-4610.2002.0420s1003.x.","journal-title":"Headache"},{"key":"1024_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0098933","volume":"9","author":"AF Smelt","year":"2014","unstructured":"Smelt AF, Louter MA, Kies DA, et al. What do patients consider to be the most important outcomes for effectiveness studies on migraine treatment? Results of a Delphi study. PLoS ONE. 2014;9:e98933. https:\/\/doi.org\/10.1371\/journal.pone.0098933.","journal-title":"PLoS ONE"},{"key":"1024_CR43","doi-asserted-by":"publisher","DOI":"10.1177\/03331024251343309","volume":"45","author":"J Ailani","year":"2025","unstructured":"Ailani J, Pavlovic J, Pixton GC, Fullerton T. Rimegepant safety and patient-reported outcomes among triptan-na\u00efve, triptan-using, and triptan-failure participants: subgroup analysis of an open-label, multicenter study. Cephalalgia. 2025;45:3331024251343309. https:\/\/doi.org\/10.1177\/03331024251343309.","journal-title":"Cephalalgia"},{"key":"1024_CR44","doi-asserted-by":"publisher","DOI":"10.1177\/03331024251352849","volume":"45","author":"SJ Tepper","year":"2025","unstructured":"Tepper SJ, Jenkins A, Henriksen C, et al. A comparison of the persistence of acute treatment with rimegepant versus oral triptans in patients with migraine: a retrospective analysis of US claims data. Cephalalgia. 2025;45:03331024251352849. https:\/\/doi.org\/10.1177\/03331024251352849.","journal-title":"Cephalalgia"},{"key":"1024_CR45","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1177\/0333102411433042","volume":"32","author":"M Lant\u00e9ri-Minet","year":"2012","unstructured":"Lant\u00e9ri-Minet M, Mick G, Allaf B. Early dosing and efficacy of triptans in acute migraine treatment: the TEMPO study. Cephalalgia. 2012;32:226\u201335. https:\/\/doi.org\/10.1177\/0333102411433042.","journal-title":"Cephalalgia"},{"issue":"Suppl 2","key":"1024_CR46","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/j.1468-2982.2008.01688.x","volume":"28","author":"A Gendolla","year":"2008","unstructured":"Gendolla A. Early treatment in migraine: how strong is the current evidence? Cephalalgia. 2008;28(Suppl 2):28\u201335. https:\/\/doi.org\/10.1111\/j.1468-2982.2008.01688.x.","journal-title":"Cephalalgia"},{"key":"1024_CR47","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/j.1468-2982.2008.01546.x","volume":"28","author":"PJ Goadsby","year":"2008","unstructured":"Goadsby PJ, Zanchin G, Geraud G, et al. Early vs.. non-early intervention in acute migraine-\u2019Act when mild (AwM)\u2019. A double-blind, placebo-controlled trial of almotriptan. Cephalalgia. 2008;28:383\u201391. https:\/\/doi.org\/10.1111\/j.1468-2982.2008.01546.x.","journal-title":"Cephalalgia"},{"key":"1024_CR48","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1046\/j.1526-4610.2000.00144.x","volume":"40","author":"RK Cady","year":"2000","unstructured":"Cady RK, Lipton RB, Hall C, Stewart WF, O\u2019Quinn S, Gutterman D. Treatment of mild headache in disabled migraine sufferers: results of the Spectrum Study. Headache. 2000;40:792\u20137. https:\/\/doi.org\/10.1046\/j.1526-4610.2000.00144.x.","journal-title":"Headache"},{"key":"1024_CR49","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1111\/head.12941","volume":"56","author":"RB Lipton","year":"2016","unstructured":"Lipton RB, Munjal S, Buse DC, Fanning KM, Bennett A, Reed ML. Predicting inadequate response to acute migraine medication: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache. 2016;56:1635\u201348. https:\/\/doi.org\/10.1111\/head.12941.","journal-title":"Headache"},{"key":"1024_CR50","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1111\/head.13835","volume":"60","author":"L Lombard","year":"2020","unstructured":"Lombard L, Ye W, Nichols R, Jackson J, Cotton S, Joshi S. A real-world analysis of patient characteristics, treatment patterns, and level of impairment in patients with migraine who are insufficient responders vs. responders to acute treatment. Headache. 2020;60:1325\u201339. https:\/\/doi.org\/10.1111\/head.13835.","journal-title":"Headache"},{"key":"1024_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-020-01848-4","volume":"20","author":"K Hirata","year":"2020","unstructured":"Hirata K, Ueda K, Ye W, et al. Factors associated with insufficient response to acute treatment of migraine in Japan: analysis of real-world data from the Adelphi Migraine Disease Specific Programme. BMC Neurol. 2020;20:274. https:\/\/doi.org\/10.1186\/s12883-020-01848-4.","journal-title":"BMC Neurol"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01024-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-01024-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01024-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T16:07:18Z","timestamp":1788970038000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-01024-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":51,"alternative-id":["1024"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-01024-9","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"assertion":[{"value":"8 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Richard B Lipton: Research support: NIH and FDA; research grants, consultant, advisory board member or honoraria: Aeon, Allergan\/AbbVie, Amgen, Axsome, Dr Reddy\u2019s Laboratories, Eli Lilly, GSK, Ipsen, Kallyope, Linpharma, Lundbeck, Pfizer, Merck, Teva,; royalties from Informa and Wolff\u2019s Headache (8th edition, Oxford University Press, 2009); stock options in Biohaven Pharmaceuticals, CoolTech, and NuVieBio. Peter J Goadsby: Consulting fees: AbbVie, CoolTech LLC, Dr Reddy\u2019s, Epalex, Ipsen, Kallyope, Linpharma, Lundbeck, Orion Pharma, Pfizer, PureTech Health LLC, Satsuma, Scilex Pharmaceuticals, Seaport Therapeutics, Septurna, and Teva Pharmaceuticals; personal fees for advice: Gerson Lehrman Group, Guidepoint, SAI Med Partners, Vector Psychometric; fees for educational materials: CME Outfitters and WebMD; publishing royalties or fees: Massachusetts Medical Society, Oxford University Press, UptoDate, and Wolters Kluwer. Patricia Pozo-Rosich: In the last 3\u00a0years, consultant and speaker: AbbVie, Almirall, Dr. Reddy\u2019s, Eli Lilly, Lundbeck, Medscape, Novartis, Organon, Otsuka Pharmaceuticals, Pfizer, Teva; research grants to her research group: AbbVie, AGAUR, EraNet Neuron, FEDER RIS3CAT, Instituto Investigaci\u00f3n Carlos III, MICINN, Novartis, Teva; funding for clinical trials: AbbVie, Amgen, Eli Lilly, Ipsen, Lundbeck, Merz, Pfizer, Teva; associate editor for Cephalalgia, European Journal of Neurology and Neurologia; founder of\n                      \n                      , a platform to give information and tools to physicians and people who suffer from migraine and other headaches. Alexandre Urani: Employee of Aptar Digital Health, which was a paid consultant to Pfizer for the conduct of this study. Giorgio Lambru: Consulting fees: AbbVie, Dr Reddy\u2019s Laboratories, Eli Lilly, Lundbeck, Pfizer, and Teva. Todd J Schwedt: In the last 24\u00a0months served as a consultant for AbbVie, Lundbeck, and Salvia, received royalties from UpToDate, had research support from AbbVie, American Heart Association, Flinn Foundation, Henry Jackson Foundation, National Headache Foundation, National Institutes of Health, Patient Centered Outcomes Research Institute, Pfizer, and US Department of Defense, and had stock options\/equity in Allevalux and Nocira. Kristina M Fanning: Managing director of MIST Research, which has received research funding from AbbVie, Allay Lamp, NYC Langone Health, Juva Health, Migraine Canada, AESARA, and Aptar. Ryan C Bostic: Employee of MIST Research. Feng Dai, Lucy Abraham, and Karin Hygge Blakeman: Employees of and own stock\/options in Pfizer.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol and all relevant documents were prospectively approved by the Advarra Institutional Review Board (Pro00079359). The study was conducted in accordance with all legal and regulatory requirements, including the Helsinki Declaration of 1964 (and later amendments), and according to good practice guidelines in relation to pharmaco-epidemiologic research. All participants provided informed consent at screening.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}